Tumour heterogeneity and resistance to cancer therapies von Dagogo-Jack, Ibiayi, Shaw, Alice T.

Volltext

Recent Advances in Targeting ROS1 in Lung Cancer von Lin, Jessica J., Shaw, Alice T.

Volltext

ALK in Lung Cancer: Past, Present, and Future von Shaw, Alice T, Engelman, Jeffrey A

Volltext

Targeting ALK: Precision Medicine Takes on Drug Resistance von Lin, Jessica J, Riely, Gregory J, Shaw, Alice T

Volltext

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer von GAINOR, Justin F, SHAW, Alice T

Volltext

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies von LOVLY, Christine M, SHAW, Alice T

Volltext

Novel Targets in Non‐Small Cell Lung Cancer: ROS1 and RET Fusions von Gainor, Justin F., Shaw, Alice T.

Volltext

Targeting Anaplastic Lymphoma Kinase in Lung Cancer von SHAW, Alice T, SOLOMON, Benjamin

Volltext

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine von Katayama, Ryohei, Lovly, Christine M, Shaw, Alice T

Volltext

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer von Shaw, Alice T, Bauer, Todd M, de Marinis, Filippo, Felip, Enriqueta, Goto, Yasushi, Liu, Geoffrey, Mazieres, Julien, Kim, Dong-Wan, Mok, Tony, Polli, Anna, Thurm, Holger, Calella, Anna M, Peltz, Gerson, Solomon, Benjamin J

Volltext

Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial von Shaw, Alice T, Dr, Gandhi, Leena, MD, Gadgeel, Shirish, Prof, Riely, Gregory J, MD, Cetnar, Jeremy, MD, West, Howard, MD, Camidge, D Ross, MD, Socinski, Mark A, Prof, Chiappori, Alberto, MD, Mekhail, Tarek, MD, Chao, Bo H, MD, Borghaei, Hossein, DO, Gold, Kathryn A, MD, Zeaiter, Ali, MD, Bordogna, Walter, PhD, Balas, Bogdana, MD, Puig, Oscar, PhD, Henschel, Volkmar, PhD, Ou, Sai-Hong Ignatius, Prof

Volltext

The Effect of Mindfulness-Based Therapy on Anxiety and Depression: A Meta-Analytic Review von Hofmann, Stefan G, Sawyer, Alice T, Witt, Ashley A, Oh, Diana

Volltext

Recent advances in ginseng as cancer therapeutics: a functional and mechanistic overview von Wong, Alice S. T, Che, Chi-Ming, Leung, Kar-Wah

Volltext

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial von Gettinger, Scott N, Dr, Bazhenova, Lyudmila A, Prof, Langer, Corey J, Prof, Salgia, Ravi, Prof, Gold, Kathryn A, MD, Rosell, Rafael, Prof, Shaw, Alice T, MD, Weiss, Glen J, MD, Tugnait, Meera, PhD, Narasimhan, Narayana I, PhD, Dorer, David J, PhD, Kerstein, David, MD, Rivera, Victor M, PhD, Clackson, Timothy, PhD, Haluska, Frank G, MD, Camidge, David Ross, Prof

Volltext

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer von Peters, Solange, Camidge, D. Ross, Shaw, Alice T, Gadgeel, Shirish, Ahn, Jin S, Kim, Dong-Wan, Ou, Sai-Hong I, Pérol, Maurice, Dziadziuszko, Rafal, Rosell, Rafael, Zeaiter, Ali, Mitry, Emmanuel, Golding, Sophie, Balas, Bogdana, Noe, Johannes, Morcos, Peter N, Mok, Tony

Volltext

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial von Shaw, Alice T, Solomon, Benjamin J, Chiari, Rita, Riely, Gregory J, Besse, Benjamin, Soo, Ross A, Kao, Steven, Lin, Chia-Chi, Bauer, Todd M, Clancy, Jill S, Thurm, Holger, Martini, Jean-Francois, Peltz, Gerson, Abbattista, Antonello, Li, Sherry, Ou, Sai-Hong Ignatius

Volltext

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models von Zou, Helen Y., Friboulet, Luc, Kodack, David P., Engstrom, Lars D., Li, Qiuhua, West, Melissa, Tang, Ruth W., Wang, Hui, Tsaparikos, Konstantinos, Wang, Jinwei, Timofeevski, Sergei, Katayama, Ryohei, Dinh, Dac M., Lam, Hieu, Lam, Justine L., Yamazaki, Shinji, Hu, Wenyue, Patel, Bhushankumar, Bezwada, Divya, Frias, Rosa L., Lifshits, Eugene, Mahmood, Sidra, Gainor, Justin F., Affolter, Timothy, Lappin, Patrick B., Gukasyan, Hovhannes, Lee, Nathan, Deng, Shibing, Jain, Rakesh K., Johnson, Ted W., Shaw, Alice T., Fantin, Valeria R., Smeal, Tod

Volltext

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global... von Camidge, D. Ross, Dziadziuszko, Rafal, Peters, Solange, Mok, Tony, Noe, Johannes, Nowicka, Malgorzata, Gadgeel, Shirish M., Cheema, Parneet, Pavlakis, Nick, de Marinis, Filippo, Cho, Byoung Chul, Zhang, Li, Moro-Sibilot, Denis, Liu, Ting, Bordogna, Walter, Balas, Bogdana, Müller, Barbara, Shaw, Alice T.

Volltext

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials von Drilon, Alexander, Siena, Salvatore, Dziadziuszko, Rafal, Barlesi, Fabrice, Krebs, Matthew G, Shaw, Alice T, de Braud, Filippo, Rolfo, Christian, Ahn, Myung-Ju, Wolf, Jürgen, Seto, Takashi, Cho, Byoung Chul, Patel, Manish R, Chiu, Chao-Hua, John, Thomas, Goto, Koichi, Karapetis, Christos S, Arkenau, Hendrick-Tobias, Kim, Sang-We, Ohe, Yuichiro, Li, Yu-Chung, Chae, Young K, Chung, Christine H, Otterson, Gregory A, Murakami, Haruyasu, Lin, Chia-Chi, Tan, Daniel S W, Prenen, Hans, Riehl, Todd, Chow-Maneval, Edna, Simmons, Brian, Cui, Na, Johnson, Ann, Eng, Susan, Wilson, Timothy R, Doebele, Robert C

Volltext

EMOTION DYSREGULATION MODEL OF MOOD AND ANXIETY DISORDERS von Hofmann, Stefan G., Sawyer, Alice T., Fang, Angela, Asnaani, Anu

Volltext